I-Mab – NASDAQ:IMAB

I-Mab stock price today

$4.06
+3.17
+361.36%
Financial Health
0
1
2
3
4
5
6
7
8
9

I-Mab stock price monthly change

-48.84%
month

I-Mab stock price quarterly change

-48.84%
quarter

I-Mab stock price yearly change

-45.34%
year

I-Mab key metrics

Market Cap
74.48M
Enterprise value
N/A
P/E
-0.83
EV/Sales
-2.04
EV/EBITDA
-18.42
Price/Sales
1.90
Price/Book
0.73
PEG ratio
N/A
EPS
-43.75
Revenue
-1.75B
EBITDA
-3.33B
Income
-3.34B
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
7.93%
Oper. margin
-11.56%
Gross margin
0%
EBIT margin
-11.56%
EBITDA margin
190.19%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

I-Mab stock price history

I-Mab stock forecast

I-Mab financial statements

I-Mab (NASDAQ:IMAB): Profit margin
Jun 2022 8.00M -161.53M -2018.7%
Dec 2022 -1.76B -2.97B 168.77%
Jun 2023 2.83M -111.49M -3931.8%
Dec 2023 1.10M -95.73M -8673.15%
I-Mab (NASDAQ:IMAB): Analyst Estimates
2025 38.80M -7.57B -19515.09%
2026 51.74M -8.71B -16844.84%
2027 21.42M -599.65M -2798.73%
2028 21.42M -634.49M -2961.34%
  • Analysts Price target

  • Financials & Ratios estimates

0%
Yield TTM
I-Mab (NASDAQ:IMAB): Payout ratio
Payout ratio 0%
I-Mab (NASDAQ:IMAB): Dividend Yield
2019 1.89%
2020
2021
2022
2023
I-Mab (NASDAQ:IMAB): Debt to assets
May 2023 3511695000 1.06B 30.32%
Jun 2023 3511695000 1.06B 30.32%
Sep 2023 2612967000 894.81M 34.25%
Dec 2023 2612967000 894.81M 34.25%
I-Mab (NASDAQ:IMAB): Cash Flow
Dec 2021 -1.98B -781.68M 53.84M
Jun 2022 -85.45M 77.04M 2.78M
Dec 2022 -2.11B 403.90M -2.78B
Jun 2023 0 0 0

I-Mab alternative data

I-Mab (NASDAQ:IMAB): Employee count
Aug 2023 378
Sep 2023 378
Oct 2023 378
Nov 2023 378
Dec 2023 378
Jan 2024 378
Feb 2024 378
Mar 2024 378
Apr 2024 378
May 2024 378
Jun 2024 378
Jul 2024 220

I-Mab other data

21.65% -1.26%
of IMAB is owned by hedge funds
37.82M -2.20M
shares is hold by hedge funds
Patent
Grant
Filling date: 25 Jan 2019 Issue date: 2 Aug 2022
Application
Filling date: 28 Dec 2021 Issue date: 21 Apr 2022
Application
Filling date: 27 Jul 2020 Issue date: 14 Apr 2022
Grant
Filling date: 12 Aug 2020 Issue date: 1 Mar 2022
Application
Filling date: 15 Feb 2019 Issue date: 24 Feb 2022
Grant
Filling date: 29 Mar 2019 Issue date: 11 Jan 2022
Grant
Filling date: 26 Apr 2020 Issue date: 28 Dec 2021
Application
Filling date: 12 Jul 2021 Issue date: 11 Nov 2021
Application
Filling date: 12 Aug 2020 Issue date: 14 Oct 2021
Application
Filling date: 20 May 2021 Issue date: 16 Sep 2021
Thursday, 21 November 2024
prnewswire.com
Thursday, 14 November 2024
prnewswire.com
Wednesday, 6 November 2024
prnewswire.com
Thursday, 31 October 2024
prnewswire.com
Wednesday, 30 October 2024
prnewswire.com
Monday, 28 October 2024
prnewswire.com
Wednesday, 9 October 2024
zacks.com
Monday, 16 September 2024
prnewswire.com
Tuesday, 10 September 2024
prnewswire.com
Wednesday, 28 August 2024
prnewswire.com
Monday, 26 August 2024
prnewswire.com
Wednesday, 14 August 2024
prnewswire.com
Wednesday, 7 August 2024
prnewswire.com
Monday, 15 July 2024
prnewswire.com
Wednesday, 5 June 2024
prnewswire.com
Thursday, 23 May 2024
globenewswire.com
Wednesday, 22 May 2024
prnewswire.com
Tuesday, 30 April 2024
prnewswire.com
Friday, 5 April 2024
prnewswire.com
Tuesday, 2 April 2024
prnewswire.com
Thursday, 14 March 2024
prnewswire.com
Sunday, 18 February 2024
Seeking Alpha
Wednesday, 7 February 2024
Reuters
Friday, 22 September 2023
Reuters
Wednesday, 13 September 2023
Seeking Alpha
Tuesday, 27 June 2023
Market Watch
Friday, 31 March 2023
Seeking Alpha
Wednesday, 5 October 2022
Zacks Investment Research
Tuesday, 27 September 2022
Seeking Alpha
Tuesday, 30 August 2022
Seeking Alpha
  • What's the price of I-Mab stock today?

    One share of I-Mab stock can currently be purchased for approximately $4.06.

  • When is I-Mab's next earnings date?

    Unfortunately, I-Mab's (IMAB) next earnings date is currently unknown.

  • Does I-Mab pay dividends?

    No, I-Mab does not pay dividends.

  • How much money does I-Mab make?

    I-Mab has a market capitalization of 74.48M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 112.48% to 27.64M US dollars.

  • What is I-Mab's stock symbol?

    I-Mab is traded on the NASDAQ under the ticker symbol "IMAB".

  • What is I-Mab's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of I-Mab?

    Shares of I-Mab can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does I-Mab have?

    As Jul 2024, I-Mab employs 220 workers, which is 42% less then previous month and 42% less then previous quarter.

  • When I-Mab went public?

    I-Mab is publicly traded company for more then 5 years since IPO on 17 Jan 2020.

  • What is I-Mab's official website?

    The official website for I-Mab is i-mabbiopharma.com.

  • How can i contact I-Mab?

    I-Mab can be reached via phone at +86 21 6057 8000.

I-Mab company profile:

Exchange:

NASDAQ

Full time employees:

34

Industry:

Biotechnology

Sector:

Healthcare

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

New Bund Center
Shanghai, 200124

CIK: 0001778016
ISIN: US44975P1030
CUSIP: 44975P103